blinatumomab (blincyto) Report issue

Biologics mAb Multi-specific Orphan Drug FDA Approved FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Blinatumomab, sold under the brand name Blincyto, is a biopharmaceutical medication used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It belongs to a class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab specifically targets the CD19 antigen present on B cells. In December 2014, it was approved by the US Food and Drug Administration under the accelerated approval program; marketing authorization depended on the outcome of clinical trials that were ongoing at the time of approval.   Wikipedia

More Chemistry
antibody mt-103 | blinatumomab | blincyto | medi-538 | mt 103 | mt-103 | mt-103 antibody | mt103 cpd | n,n-dicyclohexyl-isoborneol-10-sulfonamide

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue